Entero Therapeutics (FWBI) Revenue & Revenue Breakdown
Entero Therapeutics Revenue Highlights
Entero Therapeutics Revenue by Period
Entero Therapeutics Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | - | 100.00% |
2022-12-31 | - | 100.00% |
2021-12-31 | - | 100.00% |
2020-12-31 | - | 100.00% |
2019-12-31 | - | 100.00% |
2018-12-31 | - | 100.00% |
2017-12-31 | - | 100.00% |
2016-12-31 | - | 100.00% |
2015-12-31 | - | - |
Entero Therapeutics Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-03-31 | - | -100.00% |
2023-12-31 | $138.77K | 100.00% |
2023-09-30 | - | 100.00% |
2023-06-30 | - | 100.00% |
2023-03-31 | - | 100.00% |
2022-12-31 | - | 100.00% |
2022-09-30 | - | 100.00% |
2022-06-30 | - | 100.00% |
2022-03-31 | - | 100.00% |
2021-12-31 | - | 100.00% |
2021-09-30 | - | 100.00% |
2021-06-30 | - | 100.00% |
2021-03-31 | - | 100.00% |
2020-12-31 | - | 100.00% |
2020-09-30 | - | 100.00% |
2020-06-30 | - | -100.00% |
2020-03-31 | $2.06M | 100.00% |
2019-12-31 | - | 100.00% |
2019-09-30 | - | 100.00% |
2019-06-30 | - | 100.00% |
2019-03-31 | - | 100.00% |
2018-12-31 | - | 100.00% |
2018-09-30 | - | 100.00% |
2018-06-30 | - | 100.00% |
2018-03-31 | - | 100.00% |
2017-12-31 | - | 100.00% |
2017-09-30 | - | 100.00% |
2017-06-30 | - | 100.00% |
2017-03-31 | - | 100.00% |
2016-12-31 | - | 100.00% |
2016-09-30 | - | 100.00% |
2016-06-30 | - | 100.00% |
2016-03-31 | - | 100.00% |
2015-12-31 | - | 100.00% |
2015-09-30 | - | 100.00% |
2015-06-30 | - | 100.00% |
2015-03-31 | - | - |
Entero Therapeutics Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
SGTX | Sigilon Therapeutics | $12.94M | $5.90M |
SONN | Sonnet BioTherapeutics | $147.81K | - |
XFOR | X4 Pharmaceuticals | - | $563.00K |
PXMD | PaxMedica | - | - |
ZURA | Zura Bio | - | - |
REVB | Revelation Biosciences | - | - |
ICU | SeaStar Medical | - | - |
HILS | Tharimmune | - | - |
FWBI | Entero Therapeutics | - | - |
DRMA | Dermata Therapeutics | - | - |
CFRX | ContraFect | - | - |
PHIO | Phio Pharmaceuticals | - | - |
ZVSA | ZyVersa Therapeutics | - | - |
IMMX | Immix Biopharma | - | - |
VIRI | Virios Therapeutics | - | - |
EFTR | eFFECTOR Therapeutics | - | - |
QNRX | Quoin Pharmaceuticals | - | - |
CDIO | Cardio Diagnostics | - | $7.87K |
BWV | Onconetix | - | - |
FWBI Revenue FAQ
What is Entero Therapeutics’s yearly revenue?
Entero Therapeutics's yearly revenue for 2023 was $0, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021. FWBI's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.
What is Entero Therapeutics’s quarterly revenue?
Entero Therapeutics's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $138.77K, a 100.00% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022). FWBI's quarterly revenue for Q3 2023 was $0, a 100.00% increase from the previous quarter (Q2 2023), and a 0% increase year-over-year (Q3 2022).
What is Entero Therapeutics’s revenue growth rate?
Entero Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was 0%.